Our increased presence and participation at leading clinical conferences such as ISICEM, underscores our commitment as an emerging leader in critical care immunotherapy to 1) Support our customers with the generation of clinical data 2) Promote relevant educational content, and most importantly, 3) Work together to identify and highlight best practices for CytoSorb treatment.
In advance of ISICEM, members of the CytoSorb community from around the world will gather at Hotel Marivaux to learn about and discuss some of the most recent advances and knowledge in CytoSorb treatment for critical illnesses.
CytoSorbents Research Symposium at ISICEM Thursday, March 19, 2015, 12:30 to 1:30 PM CET, Arc Room Square - Brussels Meeting Center -- rue Mont des Arts, 1000 Brussels, Belgium
Throughout the ISICEM
meeting, Astute Medical representatives will be available at Booth1.
Data from the international study of more than 80 patients, presented to ISICEM
attendees, demonstrated that the Edwards FloTrac system is an easy-to-use and reliable method for measuring cardiac output.
symposium, entitled "New Insights into the Metabolic and Hemodynamic Status of the Critically Ill," featured several physician thought-leaders in the area of critical care.
International Symposium on Intensive Care and Emergency Medicine (ISICEM
), Brussels: Today at ISICEM
encouraging data has been presented indicating that treatment with recombinant activated factor VII (rFVIIa, marketed as NovoSeven(R)) controlled critical bleeding and reduced complications and intensive care requirements in severe blunt trauma patients enrolled into a randomised clinical trial.
These findings support and slightly improve upon similar CEG analysis data from the company's MANAGE I Study, presented at last year's ISICEM
The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Universite Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine.
The pioneering new research results being presented at ISICEM were collected from critically ill patients during GlySure's recent pilot ICU clinical trial.
At ISICEM Principal Investigator Dr Krishna Prasad will present the data from eighteen ICU patients with a broad range of conditions and co-morbidities including cardiac surgery, cerebral trauma, sepsis, diabetes and hypertension.
GlySure CEO Chris Jones said: "We are very excited by the results of the pilot ICU clinical trial and are delighted to be able to share them for the first time at ISICEM.